Status:
NOT_YET_RECRUITING
The Efficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease：A Randomized, Double-blind, Multicenter, Placebo-controlled Trial
Lead Sponsor:
Anhui Medical University
Conditions:
Parkinson Disease
Transcranial Magenetic Stimualtion
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symp...
Detailed Description
As an innovative non-invasive neuromodulation technology, repetitive transcranial magnetic stimulation (rTMS) has demonstrated efficacy in improving motor symptoms in patients with Parkinson's disease...
Eligibility Criteria
Inclusion
- Age ≥40 years old
- Meet Movement Disorder Society standards;
- Have no history of drug adjustment within 4 weeks before and during treatment;
- The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4
- MMSE ≥24，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.
Exclusion
- Head MRI/CT ruled out focal brain injury or severe leukoencephalopathy (Fazekas grade 3);
- Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);
- Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;
- There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.
- The person or first-degree relatives have a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;
- Diagnosed with a neuropsychiatric disorder other than PD
- Have a history of drug abuse or drug use;
- Participants in any clinical trial within the previous 6 month;
- Pregnant/lactating women or subjects (including men) who have a birth plan within 6 months;
- Other conditions deemed unsuitable for inclusion by the investigator.
Key Trial Info
Start Date :
November 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
312 Patients enrolled
Trial Details
Trial ID
NCT06583278
Start Date
November 1 2024
End Date
June 30 2027
Last Update
September 4 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.